Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Limited clinical benefits derived from anti-VEGF therapy have driven the identification of new targets involved in tumor angiogenesis. Here, we report an integrative meta-analysis to define the transcriptional program underlying angiogenesis in human cancer. This approach identified ELTD1, an orphan G-protein-coupled receptor whose expression is induced by VEGF/bFGF and repressed by DLL4 signaling. Extensive analysis of multiple cancer types demonstrates significant upregulation of ELTD1 in tumor-associated endothelial cells, with a higher expression correlating with favorable prognosis. Importantly, ELTD1 silencing impairs endothelial sprouting and vessel formation in vitro and in vivo, drastically reducing tumor growth and greatly improving survival. Collectively, these results provide insight into the regulation of tumor angiogenesis and highlight ELTD1 as key player in blood vessel formation.

Original publication

DOI

10.1016/j.ccr.2013.06.004

Type

Journal article

Journal

Cancer Cell

Publication Date

12/08/2013

Volume

24

Pages

229 - 241

Keywords

Animals, Cell Growth Processes, Endothelial Cells, Female, Genetic Predisposition to Disease, HCT116 Cells, Humans, Mice, Mice, Nude, Neoplasms, Neovascularization, Pathologic, Receptors, G-Protein-Coupled, Signal Transduction